Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of BPTES in preparation of medicine for preventing or treating anthracnose

An anthracnose, the technology of use, applied in the field of medicine

Active Publication Date: 2021-05-14
ZHONGSHAN HOSPITAL XIAMEN UNIV +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are currently no reports on the preventive or therapeutic effects of BPTES on anthrax

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of BPTES in preparation of medicine for preventing or treating anthracnose
  • Application of BPTES in preparation of medicine for preventing or treating anthracnose
  • Application of BPTES in preparation of medicine for preventing or treating anthracnose

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1 BPTES can inhibit macrophage death caused by anthrax toxin

[0040] J774A.1 mouse mononuclear macrophages were purchased from ATCC, DMEM medium + 10% FBS + non-essential amino acids + penicillin + streptomycin, at 37°C, 5% CO 2cultivated in the environment. BPTES (HY-12683) was purchased from MedChem Express (MCE), and dissolved in DMSO to prepare the corresponding concentration. Cells were divided into control group (Ctrl), DMSO group, BPTES 2μM group, BPTES 5μM group, BPTES 10μM group. Among them, the DMSO group, BPTES 2 μM group, BPTES 5 μM group, and BPTES 10 μM group were treated with 2 μg / mL LF+PA for 3 h, and the BPTES 2 μM group, BPTES 5 μM group, and BPTES 10 μM group were given corresponding concentrations of BPTES. The cell viability was tested using the lactate dehydrogenase (LDH) release method with the LDH detection kit from Promega.

[0041] The data were processed using GraphPad 6.0 software, expressed as mean ± standard error (means ± SEM),...

Embodiment 2

[0043] Example 2 BPTES can prevent the death of mice caused by anthrax toxin

[0044] 4-week-old female Balb / c mice were from the Experimental Animal Center of Xiamen University, and were divided into a solvent group (LF+PA) and a BPTES-administered group (LF+PA+BPTES), with N=9 in each group. The solvent group was intraperitoneally injected with vehicle (DMSO), the drug group was injected with 1 mg / kg BPTES intraperitoneally, and the solvent group and the drug group were intravenously injected with 500 mg / kg LF+PA respectively. Mice were measured up to 150 hours alive. The survival rate of mice was expressed by Kaplan-Meyer survival curve, and the log-rank (Mantel-Cox) test was performed. *p<0.05, ***p<0.001.

[0045] The result is as figure 2 As shown, 50% of the BPTES administration group survived, and all of the solvent group died, indicating that BPTES can prevent the death of mice caused by anthrax lethal toxin.

Embodiment 3

[0046] Example 3 BPTES can reduce the inflammation caused by anthrax toxin

[0047] 4-week-old female Balb / c mice were divided into control group (Ctrl), solvent group (LF+PA) and BPTES administration group (LF+PA+BPTES), each group N=4. The control group (Ctrl) was intraperitoneally injected with PBS solution, and the administration methods of the solvent group (LF+PA) and the BPTES administration group (LF+PA+BPTES) were referred to Example 2. Administration time 30min.

[0048] The mice in each group were killed, and the lungs of the mice were taken, and the wet weight and dry weight of the lungs were measured, and the ratio of the wet weight to the dry weight of the lungs was calculated by dividing the wet weight by the dry weight. The results were as follows: image 3 As shown, it was found that the pulmonary edema of mice administered with BPTES was significantly reduced.

[0049] The pleural effusion of mice in each group was drained and quantified, and the results we...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of BPTES in preparation of a medicine for preventing or treating anthracnose. The BPTES can inhibit immune cell death and mouse death caused by anthrax toxin and relieve systemic inflammation of mice, so that the BPTES can be used for preparing the medicine for preventing or treating related diseases caused by bacillus anthracis, especially anthrax toxin, and has very important application prospect and development value for anthrozoonosis such as anthrax.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a medicine for preventing or treating anthrax. Background technique [0002] Anthrax is an acute infectious disease caused by Bacillus anthracis. Humans are infected by contact with sick animals and their products and by eating meat from sick animals. The main clinical types of anthrax are cutaneous anthrax, inhalational anthrax, intestinal anthrax, and meningitis anthrax, among which cutaneous anthrax is the most common. Clinically, the main manifestations are skin necrosis, ulcers, eschar and extensive edema of surrounding tissues and symptoms of toxemia, hemorrhagic infiltration of subcutaneous and subserosal connective tissue; poor blood coagulation, coal tar-like, and occasionally can cause lung, intestinal and Acute infection of the meninges, which may be accompanied by sepsis. Under natural conditions, herbivores are the most susceptible, and humans are moderately sensitive. It ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/433A61P31/04
CPCA61K31/433A61P31/04
Inventor 王金领杨道伟齐忠全仝彩铃王煜
Owner ZHONGSHAN HOSPITAL XIAMEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com